	US 12,295,958 B2
	Ready-to-use injectable formulations
Vijaya Bharti Joshi, Portage, MI (US); Laibin Luo, Kalamazoo, MI (US); and Todd P. Foster, Kalamazoo, MI (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Appl. No. 17/435,429
Filed by Zoetis Services LLC, Parsippany, NJ (US)
PCT Filed Mar. 5, 2020, PCT No. PCT/US2020/021060 § 371(c)(1), (2) Date Sep. 1, 2021, PCT Pub. No. WO2020/181024, PCT Pub. Date Sep. 10, 2020.
Claims priority of provisional application 62/814,440, filed on Mar. 6, 2019.
Prior Publication US 2022/0125798 A1, Apr. 28, 2022
Int. Cl. A61K 31/546 (2006.01); A61K 9/00 (2006.01); A61K 47/14 (2017.01)

CPC A61K 31/546 (2013.01) [A61K 9/0019 (2013.01); A61K 47/14 (2013.01)]

13 Claims

1. A ready-to-use injectable composition comprising cefovecin sodium, propylene glycol dicaprylate/dicaprate in the amount of about 58 w/w % to about 68 w/w % of the total weight of the composition and benzyl benzoate in the amount of about 12 w/w % to about 25 w/w % of the total weight of the composition, and wherein the concentration of cefovecin sodium is about 120 mg/mL to about 180 mg/mL, and wherein the composition is a suspension.